DXCM

DXCM

USD

DexCom Inc. Common Stock

$61.180+0.090 (0.147%)

Prix en Temps Réel

Healthcare
Dispositifs médicaux
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$61.090

Haut

$62.390

Bas

$58.880

Volume

8.96M

Fondamentaux de l'Entreprise

Capitalisation Boursière

23.9B

Industrie

Dispositifs médicaux

Pays

United States

Statistiques de Trading

Volume Moyen

5.54M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $56.45Actuel $61.180Haut $93.25

Rapport d'Analyse IA

Dernière mise à jour: 4 nov. 2025
Généré par l'IASource des Données: Yahoo Finance, Bloomberg, SEC

DXCM Analysis: DexCom's Rocky Road - Can Recent Bounce Hold?

Market Pulse Check

  • Current Price: $60.43 (as of 2025-11-03 close)
  • Recent Swing: +3.8% rebound after 61% decline since August highs
  • Key Technicals: MACD bearish crossover vs. surging 19x average volume

Price Action Breakdown

  • August-Sept Stability: Traded $75-$82 range
  • Sept 19 Crash: -11% drop on 3x average volume
  • October Freefall: 35% decline accelerated by legal news
  • November Lifeline: +3.8% gain on massive 17.8M shares traded

News Impact Matrix

SentimentCountKey Developments
Negative96 law firm investigations filed
Analyst Mixed128 lowered PTs (range $75-$99)
Positive1New board member appointment

AI Forecast Snapshot

TimeframePredictionNotes
1-day-0.8%Potential pullback after surge
2-day+1.6%Technical rebound potential
3-day+1.9%Resistance near $62 area

Strategic Considerations

For Active Traders:

  • Watch $61.15 breakout level (Nov 3 high)
  • Consider partial profits at $62.90 TP
  • Hard stop below $58.50 support

Long-term Investors:

  • Monitor lawsuit developments closely
  • Debt concerns (94% D/E ratio) require scrutiny
  • Potential accumulation zone if $58 holds

Bottom Line

DexCom's technical bounce faces fundamental headwinds. While AI models suggest near-term upside, the legal overhang creates exceptional risk. The stock needs to reclaim $62 decisively to suggest sustainable recovery. Healthcare sector exposure remains favorable, but DXCM requires tighter risk parameters than peers.


This analysis reflects market conditions as of November 4, 2025. Consider consulting a financial advisor before making investment decisions. Past performance doesn't guarantee future results. Data sources: Analyst reports, SEC filings, market data feeds.

Actualités Connexes

PR Newswire

Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. (NASDAQ:...

Voir plus
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit
Analyst Upgrades

UBS Maintains Buy on DexCom, Lowers Price Target to $95

UBS analyst Danielle Antalffy maintains DexCom with a Buy and lowers the price target from $106 to $95.

Voir plus
UBS Maintains Buy on DexCom, Lowers Price Target to $95
Analyst Upgrades

Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82

Truist Securities analyst Richard Newitter reiterates DexCom with a Buy and lowers the price target from $94 to $82.

Voir plus
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82
Analyst Upgrades

Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80

Barclays analyst Matt Miksic maintains DexCom with a Equal-Weight and lowers the price target from $98 to $80.

Voir plus
Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80
PR Newswire

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or...

Voir plus
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR Newswire

DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM) - Contact Kessler Topaz Meltzer & Check, LLP

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against...

Analyst Upgrades

Wells Fargo Maintains Overweight on DexCom, Lowers Price Target to $93

Wells Fargo analyst Larry Biegelsen maintains DexCom with a Overweight and lowers the price target from $98 to $93.

Prédiction IABeta

Recommandation IA

Haussier

Mis à jour le: 4 nov. 2025, 21:09

BaissierNeutreHaussier

60.6% Confiance

Risque et Trading

Niveau de Risque3/5
Risque Moyen
Adapté Pour
AgressifConservateurCroissance
Guide de Trading

Point d'Entrée

$58.80

Prise de Bénéfices

$62.91

Stop Loss

$52.39

Facteurs Clés

Le DMI montre une tendance baissière (ADX:15.5, +DI:9.8, -DI:18.9), suggérant la prudence
Le volume de transactions est 19.6x la moyenne (59,957), indiquant une pression d'achat extrêmement forte
Le MACD -0.1446 est en dessous de la ligne de signal -0.0199, indiquant un croisement baissier

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.